XORTX Therapeutics (XRTX) Other financing activities (2020 - 2026)
XORTX Therapeutics' (XRTX) quarterly Other financing activities came in at -$81968.0 in Q1 2026, down 258.74% YoY from $51637.4 in Q1 2025, and up 69.78% on a QoQ basis from -$271208.0 in Q3 2025.
XORTX Therapeutics (XRTX) Other financing activities (2020 - 2026) Analysis & Trends
XORTX Therapeutics (XRTX) has 6 years of Other financing activities data on file, last reported at -$81968.0 in Q1 2026.
- Quarterly Other financing activities fell 258.74% year-over-year to -$81968.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$372240.0 (down 16.16% YoY) and the FY2022 annual result came in at $3.9 million, up 5736.55% from the prior year.
- Other financing activities rose to -$81968.0 in Q1 2026, from -$271208.0 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $3785.0 in Q2 2025 to a low of -$297607.0 in Q1 2024.
- A 4-year average of -$112676.2 and a median of -$52408.5 in 2025 frame the typical range for Other financing activities.
- Annual changes were most pronounced in 2024 — Other financing activities slumped 4692.38% — and 2025, when it jumped 92.32%.
- Tracing XRTX's Other financing activities over 4 years: stood at -$6210.0 in 2023, then tumbled by 4692.38% to -$297607.0 in 2024, then advanced by 8.87% to -$271208.0 in 2025, then jumped by 69.78% to -$81968.0 in 2026.
- The last three Other financing activities figures came in at -$81968.0 (Q1 2026), -$271208.0 (Q3 2025), and $3785.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.78 Bn | 131.93 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.58 Bn | 78.59 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn |
| 4 | Moderna | 58.86 Bn | 53.73 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.73 Bn | 28.42 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.19 Bn | 9.80 Bn | 668.28 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - |
| 10 | XORTX Therapeutics | 2.84 Mn | 2.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -81,968.00 |
| Mar 31, 2026 | -81,968.00 |
| Sep 30, 2025 | -271,208.00 |
| Sep 30, 2025 | -271,208.00 |
| Jun 30, 2025 | 3,785.00 |
| Jun 30, 2025 | 3,785.00 |
| Mar 31, 2025 | -22,849.00 |
| Mar 31, 2025 | -22,849.00 |
| Mar 31, 2024 | -297,607.00 |
| Mar 31, 2024 | -297,607.00 |
| Mar 31, 2023 | -6,210.00 |
| Mar 31, 2023 | -6,210.00 |
| Dec 31, 2021 | -1.12 Mn |
| Dec 31, 2021 | -1.12 Mn |
| Sep 30, 2021 | 378,200.00 |
| Sep 30, 2021 | 378,200.00 |
| Mar 31, 2021 | 801,165.25 |
| Mar 31, 2021 | 801,165.25 |
| Dec 31, 2020 | 1.27 Mn |
| Dec 31, 2020 | 1.27 Mn |